Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-RAPID infliximab pharmacokinetic study in pediatric Crohn's disease
NL-OMON60989Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Erasmus MC. Started May 2024; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON60989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60989.